This can be attributed to both the rapid advancement in China’s research capabilities and its large population of ALK-positive NSCLC patients, given the high prevalence of lung cancer in the country (Han et al., 2024; Gou and Wu, 2014; Yang et al., 2016). This evidence concerns the gene ALK and lung carcinoma.